FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
2.37B
Enterprise Value 3
2.16B
Trailing P/E
N/A
Forward P/E 1
-9.46
PEG Ratio (5 yr expected) 1
7.60
Price/Sales (ttm)
14.84
Price/Book (mrq)
4.31
Enterprise Value/Revenue 3
13.54
Enterprise Value/EBITDA 6
-7.74

Trading Information

Stock Price History

Beta (5Y Monthly) 1.54
52-Week Change 3-13.02%
S&P500 52-Week Change 325.71%
52 Week High 314.62
52 Week Low 37.11
50-Day Moving Average 39.78
200-Day Moving Average 39.91

Share Statistics

Avg Vol (3 month) 33.13M
Avg Vol (10 day) 33.47M
Shares Outstanding 5255.42M
Float 204.59M
% Held by Insiders 10.99%
% Held by Institutions 1108.93%
Shares Short (Dec 30, 2019) 433.26M
Short Ratio (Dec 30, 2019) 49.12
Short % of Float (Dec 30, 2019) 414.49%
Short % of Shares Outstanding (Dec 30, 2019) 413.05%
Shares Short (prior month Nov 28, 2019) 432.1M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin -216.02%
Operating Margin (ttm)-176.23%

Management Effectiveness

Return on Assets (ttm)-20.43%
Return on Equity (ttm)-71.88%

Income Statement

Revenue (ttm)159.59M
Revenue Per Share (ttm)0.71
Quarterly Revenue Growth (yoy)136.80%
Gross Profit (ttm)76.84M
EBITDA -279.2M
Net Income Avi to Common (ttm)-344.74M
Diluted EPS (ttm)-1.54
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)514.19M
Total Cash Per Share (mrq)2.02
Total Debt (mrq)205.3M
Total Debt/Equity (mrq)37.45
Current Ratio (mrq)6.20
Book Value Per Share (mrq)2.15

Cash Flow Statement

Operating Cash Flow (ttm)-253.26M
Levered Free Cash Flow (ttm)-156.64M